Literature DB >> 34481260

Tele-buprenorphine for emergency department overdose visit follow up and treatment initiation.

Rachel S Wightman1, Brendan Jacka2, Julia Uber3, Michelle McKenzie4, Neha G Reddy5, Roger Winters5, Lee Ann Jordison Keeler6, Elizabeth A Samuels6.   

Abstract

INTRODUCTION: An ED visit for opioid overdose may be a person's only contact with the medical and behavioral health care systems and is an important opportunity to reduce risk of subsequent overdose and death. While ED initiatives to engage people with opioid use disorder (OUD) are being increasingly implemented, there are significant gaps in the receipt of services at the time of the ED encounter.
METHODS: This is a retrospective cohort study of an outreach pilot project providing real-time telehealth delivered buprenorphine initiation and referral to community harm reduction and addiction treatment services via a follow up telephone call to patients after an ED visit for an opioid overdose.
RESULTS: From January 2020 to April 2021 there were 606 patients with an ED visit for an opioid overdose eligible for a callback. Of the 606 eligible patients, 254/645 (42%) patients could be contacted and accepted service and/or treatment referrals. Fifteen patients were connected same-day to a buprenorphine prescriber for a telehealth encounter and, of connected patients, nine received a buprenorphine prescription.
CONCLUSION: A post-ED follow up telephone call protocol is an opportunity to improve treatment engagement and access to buprenorphine for patients at high risk for opioid overdose and death.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Buprenorphine treatment; Healthcare access; Medications for opioid use disorder; Opioid use disorder; Overdose; Telehealth

Mesh:

Substances:

Year:  2021        PMID: 34481260      PMCID: PMC8665045          DOI: 10.1016/j.ajem.2021.08.071

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  7 in total

1.  One-Year Mortality of Patients After Emergency Department Treatment for Nonfatal Opioid Overdose.

Authors:  Scott G Weiner; Olesya Baker; Dana Bernson; Jeremiah D Schuur
Journal:  Ann Emerg Med       Date:  2019-06-20       Impact factor: 5.721

2.  Co-occurring substance use and mental disorders among adults with opioid use disorder.

Authors:  Christopher M Jones; Elinore F McCance-Katz
Journal:  Drug Alcohol Depend       Date:  2019-02-14       Impact factor: 4.492

3.  One-Year Mortality After Emergency Department Visit for Nonfatal Opioid Poisoning: A Population-Based Analysis.

Authors:  Pamela Leece; Cynthia Chen; Heather Manson; Aaron M Orkin; Brian Schwartz; David N Juurlink; Tara Gomes
Journal:  Ann Emerg Med       Date:  2019-09-24       Impact factor: 5.721

4.  Factors associated with opioid overdose: a 10-year retrospective study of patients in a large integrated health care system.

Authors:  Joseph A Boscarino; H Lester Kirchner; James M Pitcavage; Vijay R Nadipelli; Naoko A Ronquest; Michael H Fitzpatrick; John J Han
Journal:  Subst Abuse Rehabil       Date:  2016-09-16

Review 5.  Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.

Authors:  Luis Sordo; Gregorio Barrio; Maria J Bravo; B Iciar Indave; Louisa Degenhardt; Lucas Wiessing; Marica Ferri; Roberto Pastor-Barriuso
Journal:  BMJ       Date:  2017-04-26

6.  An Epidemic in the Midst of a Pandemic: Opioid Use Disorder and COVID-19.

Authors:  G Caleb Alexander; Kenneth B Stoller; Rebecca L Haffajee; Brendan Saloner
Journal:  Ann Intern Med       Date:  2020-04-02       Impact factor: 25.391

7.  Emergency Department Visits for Nonfatal Opioid Overdose During the COVID-19 Pandemic Across Six US Health Care Systems.

Authors:  William E Soares; Edward R Melnick; Bidisha Nath; Gail D'Onofrio; Hyung Paek; Rachel M Skains; Lauren A Walter; Martin F Casey; Anthony Napoli; Jason A Hoppe; Molly M Jeffery
Journal:  Ann Emerg Med       Date:  2021-03-19       Impact factor: 5.721

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.